More News

06 Jan 2022 POLARISqb and PhoreMost announce a multi-target collaboration to investigate next-generation cancer therapies
06 Jan 2022 Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
06 Jan 2022 Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases
05 Jan 2022 Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference
05 Jan 2022 Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
03 Jan 2022 Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology Pipeline of Tumor Microenvironment Activated Therapeutics
29 Dec 2021 AstraZeneca and Ionis close agreement to develop and commercialise eplontersen
28 Dec 2021 Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China
22 Dec 2021 Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-stage Programs and New Research Collaboration
22 Dec 2021 Heat Biologics Announces Planned Acquisition of Elusys Therapeutics
22 Dec 2021 Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
21 Dec 2021 Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics
21 Dec 2021 Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics
17 Dec 2021 Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership
17 Dec 2021 Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
16 Dec 2021 Rakuten Medical Announces FDA Acceptance of an Investigational New Drug (IND) Application for RM-1995, a Conjugate of IR700 and anti-CD25 Antibody
16 Dec 2021 Chugai In-Licenses Gene Therapy Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy
14 Dec 2021 Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
14 Dec 2021 Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
14 Dec 2021 CSL Limited Announces Tender Offer To Acquire Vifor Pharma Ltd
14 Dec 2021 Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology
13 Dec 2021 Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products
13 Dec 2021 Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform
13 Dec 2021 Pfizer to Acquire Arena Pharmaceuticals
10 Dec 2021 Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up